Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Misoprostol for the Healing of Small Bowel Ulcers in Low-dose Aspirin Users Complicated by Small Bowel Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Suspected small bowel overt bleeding - melena or hematochezia with normal upper endoscopy and colonoscopy~2. Suspected small bowel occult blood loss - defined as a significant decrease in hemoglobin (≥ 2g/dL), with normal upper endoscopy and colonoscopy, confirmed iron deficiency anemia, and absence of other identifiable causes for hemoglobin decrease (e.g. fluid overload, progressive renal failure, malnutrition, or other hematological disorders such as hemolysis or malignancies)~3. Continuous use of ASA for the duration of the trial~4. Age ≥ 18~5. Written informed consent obtained~Exclusion criteria:~Patients are excluded if they have one or more of the following conditions~1. Increased risk of capsule retention (e.g. Gastric outlet obstruction, bypass surgery, Crohn's disease or suspected small bowel stricture)~2. Abnormal findings on upper endoscopy (e.g. Esophageal varices, grade C or D erosive esophagitis, vascular malformations, ulcer, ≥5 erosions, neoplasms) or colonoscopy (e.g. cancer, polyps \> 1cm, inflammatory bowel disease, vascular malformations, bleeding hemorrhoids or diverticular disease)~3. Unable to swallow the video capsule~4. Terminal illness~5. Concomitant use of NSAIDs, sucralfate, rebamepide, anticoagulants, corticosteroids (prednisolone \> 7.5mg daily or equivalent), and iron supplement~6. Pregnancy or women of child-bearing age without regular use of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Misoprostol (Type: ACTIVE_COMPARATOR): ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
- Placebo misoprostol (Type: PLACEBO_COMPARATOR): ASA 100 mg daily + placebo misoprostol four times daily (placebo group)

Based on this trial design, predict the completion outcome and termination type (if applicable).